Canada Ditches Moderna Booster For Pfizer Over Myocarditis Risk In Young Men

Canada has become the latest country to recommend that young people – in this case boys and men aged 12 through 29 – should opt for the Pfizer Covid-19 booster shot over Moderna’s Spikevax due to a higher risk of myocarditis.

On Page 7 of Canada’s National Advisory Committee on Immunization’s revised guidelines, the new guidance calls for the Pfizer-BioNTech offering due to “Lower reported cases of myocarditis/pericarditis … compared to Moderna Spikevax.

Canada’s Chief Public Health Officer Dr. Theresa Tam explained the decision in a Friday tweet, noting that “The latest data suggests the rare risk of these events following vaccination with mRNA COVID-19 vaccines (most often seen in males 12-29 yrs) may be lower with Pfizer-BioNTech Comirnaty (30 mcg) compared to Moderna Spikevax (100 mcg) vaccine,” while a “longer interval between 1st & 2nd dose of a primary series results in stronger immune response/higher vaccine effectiveness + may be associated with lower risk of myocarditis &/or pericarditis in teens & young adults.” – READ MORE

Responses